Autopsy report · NCT02159248

Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation

“The study closed prior to enrolling any participants.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Orlando Health, Inc.

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

Tolfenamic acid + gemcitabine + radiation

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
  “Study closed before total enrollment met.” (86% match in meaning)
• Reconstruction Flaps for Nasal Surgical Wounds RCT
  “Study closed before enrollment could begin.” (83% match in meaning)
• Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
  “Study closed before patients enrolled” (81% match in meaning)
• Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
  “The study was closed to enrollment due to slow accrual.” (79% match in meaning)
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
  “The study was closed due to continued enrollment hurdles.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.